Panacea Biotec has a rich experience in the research, development, production and marketing of products in the field of Tuberculosis (TB). Panacea Biotec has been marketing its branded second line TB – drugs for the last 20 years.
Panacea Biotec has a Novel Drug Delivery based patented fixed dose formulation of four basic TB drugs under the family brand Xeed. Patents for the technology have been granted in several countries across the Globe.
TB is an infectious bacterial disease caused by Mycobacterium tuberculosis, which most commonly affects the lungs. It is transmitted from person to person via droplets from the throat and lungs of people with the active respiratory disease. In healthy people, infection with Mycobacterium tuberculosis often causes no symptoms, since the person's immune system acts to “wall off” the bacteria.
TB is a contagious disease. Like the common cold, it spreads through the air. Only people who are sick with TB in their lungs are infectious. When infectious people cough, sneeze, talk or spit, they propel TB germs, known as bacilli, into the air. The symptoms of active TB of the lung are coughing, sometimes with sputum or blood, chest pains, weakness, weight loss, fever and night sweats. Tuberculosis is treatable with a six-month course of antibiotics. Left untreated, each person with active TB disease will infect on average between 10 and 15 people every year.
It is estimated that 2 billion people, equal to one-third of the world’s total population, are infected with the TB bacillus, the microbes that cause TB. 1.6 million people died from TB and 8.8 million new TB cases in 2005.
|
